Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.72 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934384 | 0.98 | PTPN1 (0.72) | PTPN1PTPN2CA12CA1CA2 | |
| SCHEMBL2937383 | 0.88 | PTPN1 (0.57) | PTPN1PTPN2MAOAMAOBS1PR4 | |
| Potassium SCHEMBL2938040 | 0.85 | PTPN1 (0.98) | PTPN1PTPN2 | |
| Potassium SCHEMBL629904 | 0.81 | PTPN1 (0.73) | PTPN1PTPN2 | |
| SCHEMBL629875 | 0.81 | PTPN1 (0.67) | PTPN1PTPN2 | |
| SCHEMBL628450 | 0.81 | PTPN1 (0.69) | PTPN1PTPN2 | |
| Potassium SCHEMBL2931983 | 0.81 | PTPN1 (0.72) | PTPN1PTPN2 | |
| SCHEMBL629994 | 0.80 | PTPN1 (0.75) | PTPN1PTPN2 | |
| SCHEMBL629556 | 0.80 | PTPN1 (0.75) | PTPN1PTPN2 | |
| SCHEMBL22893525 | 0.80 | PTPN2 (0.80) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | claimed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | claimed |
| CN-105476990-A | Oral anti-diabetic pharmaceutical composition | ZHU ZHONGLIANG | 2016-04-13 | — | — | CN | disclosed |
| CN-105193801-A | Diabetes mellitus resistant oral medicine composition | ZHU ZHONGLIANG | 2015-12-30 | — | — | CN | disclosed |
| CN-105193800-A | Diabetes mellitus resistant oral medicine composition | ZHU ZHONGLIANG | 2015-12-30 | — | — | CN | disclosed |
| CN-105193821-A | Diabetes mellitus resistant oral medicine composition | ZHU ZHONGLIANG | 2015-12-30 | — | — | CN | disclosed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| EP-2227245-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| WO-2009068689-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 25/4885PTPN2 10/4885CA12 3747/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885PTPN2 49/4885CA12 3963/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885PTPN2 39/4885CA12 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.